האיחוד האירופי -
סלובנית -
EMA (European Medicines Agency)
adakveo
novartis europharm limited - crizanlizumab - anemija, srčna celica - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
סלובניה -
סלובנית -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
dicitirox 50 mikrogramov tablete
teva pharma b.v. - natrijev levotiroksinat - tableta - natrijev levotiroksinat 50 µg / 1 tableta - natrijev levotiroksinat
סלובניה -
סלובנית -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
dicitirox 25 mikrogramov tablete
teva pharma b.v. - natrijev levotiroksinat - tableta - natrijev levotiroksinat 25 µg / 1 tableta - natrijev levotiroksinat
סלובניה -
סלובנית -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
dicitirox 50 mikrogramov tablete
teva pharma b.v. - natrijev levotiroksinat - tableta - natrijev levotiroksinat 50 µg / 1 tableta - natrijev levotiroksinat
סלובניה -
סלובנית -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
dicitirox 100 mikrogramov tablete
teva pharma b.v. - natrijev levotiroksinat - tableta - natrijev levotiroksinat 100 µg / 1 tableta - natrijev levotiroksinat
האיחוד האירופי -
סלובנית -
EMA (European Medicines Agency)
jakavi
novartis europharm limited - ruksolitinib (kot fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastična sredstva - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi je indiciran za zdravljenje odraslih bolnikov z polycythaemia vera, ki so odporne ali nestrpne hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
סלובניה -
סלובנית -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
cyclo-progynova obložene tablete
bayer d.o.o. - estradiolvalerat; norgestrel - obložena tableta - estradiolvalerat 2 mg / 1 tableta norgestrel0,5 mg / 1 tableta; norgestrel 0,5 mg / 1 tableta - norgestrel in estrogen
סלובניה -
סלובנית -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
dicitirox 150 mikrogramov tablete
teva pharma b.v. - natrijev levotiroksinat - tableta - natrijev levotiroksinat 150 µg / 1 tableta - natrijev levotiroksinat